Aspirin resists gastrointestinal cancer

According to the new study, scientists from Veterans Affairs in Texas suggested that the pain-relief medication's interaction with platelets, the blood cells that form clots to stop bleeding, could stop tumors from growing.
Low doses of aspirin permanently reduce the chances of growth of liver and stomach cancer and most other internal organs associated with the digestive system.

Chinese scientists made the remark at the UEG-2017 Gastroenterology Conference in Barcelona recently.

Kelvin Tsui of the Chinese University of Hong Kong said researchers had shown that taking aspirin regularly for a long period of time reduced the risk of many types of cancer, including cancer of the digestive organs in particular.

In recent years, scientists have been interested in aspirin and other salicylic acid-based drugs because, as the experiments have shown, they have effective anti-cancer properties.

Aspirin trials have shown that it increases the effectiveness of the treatment to strengthen human immunity, and can fight rectal cancer, blood and a number of other tumors, and increase the chances of survival after chemotherapy by 15-20%.

The study of the world involved Tsui and his colleagues with more than 600,000 patients, some of whom took low doses of aspirin permanently for 8 years, while others ate only during periods of treatment or never ate.

The results also showed that taking aspirin permanently reduced the risk of liver and esophageal cancer by 47%.

It is worth mentioning that it is recommended to take aspirin for those who do not suffer from cardiovascular disease, it is better to consult your doctor before starting to use the medicine.